Is there a glimmer of light at the end of the tunnel?Massive expenses of the merger hopefully coming to an end after this quarter. Sales weren't horrible compared to corresponding 2023 quarter. Looks like they are focusing on PGX and Ceapro products. Discontinuing costly AEZS pipe dreams.
"In contrast, the projected
timelines and costs to reach the next value inflection point in the pre-clinical auto-immune
modifying disease (“AIMS Biologicals”) platform and Delayed Clearance Parathyroid
Hormone ("DC-PTH", AEZS-150) fusion proteins program are increasingly challenging
and, as a result, we have made the decision to discontinue further investment in these
programs,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of COSCIENS."